This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
In humans, systemic metabolism of brimonidine is extensive. This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products.
(Also refer to Adverse Reactions section).Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.Events occurring in approximately 3-9% of the subjects, in descending order included cor-neal staining/erosion, photophobia, eyelid erythemia, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain.The following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope.The following events have been identified during post-marketing use of brimonidine tartrate ophthalmic solution 0.2% in clinical practice. In solution, brimonidine tartrate ophthalmic solution 0.2% has a clear, greenish-yellow color. Call your doctor or get medical Apnea, bradycardia, hypotension, hypothermia, hypotonia, and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solution 0.2%. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), antihypertensives and/or cardiac glycosides is advised.Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. Urinary excretion is the major route of elimination of the drug and its metabolites. Brimonidine Tartrate Ophthalmic Solution 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use.
Metronidazole is primarily used to treat: bacterial vaginosis, pelvic inflammatory disease (along with other antibacterials like ceftriaxone), pseudomembranous colitis, aspiration pneumonia, rosacea (topical), fungating wounds (topical), intra-abdominal infections, lung abscess, periodontitis, amoebiasis, oral infections, giardiasis, trichomoniasis, and infections caused by susceptible anaerobic organisms such as Bacteroides, Fusobacterium, Clostridium, Peptostreptococcus, and Prevotella species. It has a peak ocular hypotensive effect occurring at two hours post-dosing. WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Because they are reported voluntarily from a population of unknown size, estimates and frequency cannot be made.
Read all information given to you. Brimonidine tartrate ophthalmic solution 0.2% is not recommended for use in pediatric patients under the age of 2 years. This is not a list of all drugs or health problems that interact with brimonidine (ophthalmic). Available for Android and iOS devices.We comply with the HONcode standard for trustworthy health information - In rosacea it improves the redness. Some products are used to treat eye redness. Brimonidine tartrate has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.In comparative clinical studies with timolol 0.5%, lasting up to one year, the IOP lowering effect of brimonidine tartrate ophthalmic solution 0.2% was approximately 4-6 mmHg compared with approximately 6 mmHg for timolol. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling brimonidine tartrate ophthalmic solution 0.2% to insert soft contact lenses.As with other drugs in this class, brimonidine tartrate ophthalmic solution 0.2% may cause fatigue and/or drowsiness in some patients. Metronidazole is an anti infectious agent. Dosing at this level produced 100 times the plasma drug concentration level seen in humans following multiple ophthalmic doses.There are no adequate and well-controlled studies in pregnant women. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.General: Although brimonidine tartrate ophthalmic solution 0.2% had minimal effect on blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.Brimonidine tartrate ophthalmic solution 0.2% has not been studied in patients with hepatic or renal impairment; caution should be used in treating such patients.Brimonidine tartrate ophthalmic solution 0.2% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans.During the studies there was a loss of effect in some patients.